Wound healing is inextricably linked to adequate tissue perfusion. In fact, most wound care protocols include a non-invasive vascular test as part of the initial work-up for a patient with a non-healing wound. Depending on the composition and expertise of the wound center’s medical staff, many patients are referred to a vascular lab, vascular surgeon, or vascular interventionalist for this initial assessment. Classically trained vascular specialists focus on macro-vascular testing, such as Doppler based segmental pressures, waveforms, pulse volume recordings, duplex scanning, and ultimately, some form of angiography if the non-invasive testing is positive.
Learning objectives 1. Describe why, when, with whom, and where to use a vena cava filter
2. Discuss why imaging the vena cava is important 3. Compare and contrast “tried and true” vs state-of-the-art technology
4. Utilize appropriate techniques for placing and retrieving filters 5.Avoid complications in the use of vena cava filters.
6. Explore ways to build successful referral patterns.
This activity is supported by an educational grant from Cook Incorporated and has been designed for Interventional Cardiology, Vascular Surgeons, Fellows and Interventional Cardiovascular Nurses and Technologists.
Topics 1. EVA-3S & Space-Bumps in the road 2. CAPTURE 3500-Lesion morphology & Predictors for Stroke 3. CAPTURE II vs. EXACT 1500-Does open or Closed Cell Stent design really matter?
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Neurologists, Interventional Nurses and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.
This activity has been developed for Interventional Cardiologists, Vascular Surgeons, Interventional Radiologists, Podiatric Physicians, Endovascular Allied Professionals, Endocrinologists, Wound Care Specialists, Directors of the Wound Care Clinic, and Primary Care Physicians, Pharmacists, Nurses and Technologists.
This activity has been developed for Physicians, Pharmacists, Nurses, and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.
This activity has been developed for Physicians, Pharmacists, Nurses, and Technologists with an interest in the diagnosis and treatment of peripheral artery disease.
Presented By: Tony Das, MD, Director of Peripheral Interventions, Presbyterian Hospital
ARTICLES
NEWS
Clinical Review: Long-Term Safety and Economic Impact of Drug-Euting Stents Eugene K. Soh, MD and Mark A. Turco, MD
Drug-eluting stents (DES) were designed to prevent neointimal proliferation via the controlled release of antiproliferative agents. Two such DES have been approved for use in the United States. The sirolimus-eluting Cypher stent (SES, Cordis Corporation, Miami Lakes, Florida) and paclitaxel-eluting TAXUS stent (PES, Boston Scientific Corporation, Natick, Massachusetts) were approved for use after randomized controlled clinical trials demonstrated their superiority over bare-metal stents (BMS) at reducing restenosis rates and the need for repeat revascularization.
Case Study: Endovascular Repair of Abdominal Aortic Aneurysm Revealed by Reversible Segmental Colonic Ischemia
Jacques Busquet, MD, Thierry Watrin, MD, Stéphane Verdeille, MD, Liliana Henao, MD, Jérôme Kusmierek, MD, Daniel Charlon, MD
Purpose. To describe a case of abdominal aortic aneurysm (AAA) initially revealed by reversible segmental colonic ischemia and to put emphasis on the significance of inferior mesenteric artery (IMA) status before planning endovascular treatment for aneurysm exclusion. Case Description. A 79-year-old man presented with recent onset of acute abdominal syndrome with left lateralized pain, distension, and ileus.
Clinical Decision Making:
Acute Inflow Stenosis — A Rare Cause of Sudden AV Fistula Failure in an ESRD Patient Kumaran Chinnappan, MD, Mahalingam Sivakumar, MD, FACS, H. T. Girishkumar, MD, FACS
The arteriovenous (AV) fistula is regarded as the vascular access of choice for hemodialysis (HD) because of its superior patency and low complication rates. Even so, this type of vascular access can result in severe complications, among them, thrombosis of the shunt. This complication usually results from stenotic lesions in the venous outflow system.
Terumo Partners with GHX for More Efficient Electronic Ordering Capabilities
SOMERSET, NJ – Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation (TMC), announces a new partnership between TMC and Global Health Exchange (GHX); expanding its reputation for supplying technologically advanced quality to supply chain management.
Working with GHX and its Electronic Data Interchange (EDI) system, Terumo Interventional Systems is looking to deliver providers what they want—when they want it. Through this e-commerce platform’s unique, streamlined process, hospitals are now easily able to place orders, generate receipts, and change and track orders with Terumo.
ANGIODYNAMICS ANNOUNCES PLAN TO LAUNCH
NEVERTOUCH™ VENACURE® PRODUCT LINE
QUEENSBURY, N.Y. (April 2, 2007) – AngioDynamics, Inc. (NASDAQ: ANGO) announced today plans to launch the NeverTouch VenaCure procedure kit for laser treatment of severe varicose veins. The improved VenaCure design will employ a proprietary laser fiber technology designed to provide an enhanced level of perforation protection by further preventing contact between the fiber tip and the vessel wall during treatment.
Press Release: Targeted Renal Therapy for Patients at Risk for Contrast-Induced NephropathyMulticenter Registry Results Presented at Society of Interventional Radiology Meeting
Data from a multicenter registry of targeted renal therapy (TRT™) in patients at high risk for contrast-induced nephropathy (CIN) – a significant cause of kidney failure and a large unmet market need
First International Trial of Drug-Eluting Peripheral Artery Stent Results Encouraging
Cook Medical’s ZILVER PTX Paclitaxel-Eluting Stent (DES) trial results demonstrated no stent fractures. The major adverse event (MAE) rate was equivalent to conventional balloon angioplasty treatment at its six-month follow-up point, as reported by the trial’s national principal investigator.
This activity is designed for Invasive Cardiologists, Vascular Surgeons, Interventional Neurologists, Interventional Radiologists, Nurses and Technologists.
Topics include direct thrombin inhibition, use of direct thrombin inhibitors during PPI, and adjunctive pharmacology during carotid artery stenting.
Dr. Zvonimir Krajcer is a Clinical Professor of Medicine at Baylor College of Medicine and at the University of Texas Health Science Center in Houston. Dr. Krajcer has pioneered a technique of non-surgical repair of abdominal aortic aneurysms with stent grafts. His special area of interest is non-surgical treatment of peripheral vascular disease with stents and stent grafts.
SPECIAL SUPPLEMENT: 
Complimentary Accredited Booklet and CD-Rom
Using Advanced Technology to
Treat Occluded Below-the-Knee Arteries
Superior Mesenteric Artery Revascularization and
Retrograde Visualization
